Modern principles of osteoporosis therapy
- Autores: Zhugrova E.S.1, Mazurov V.I.1
-
Afiliações:
- I.I. Mechnikov North-Western state medical university of the Ministry of Healthcare of Russia
- Edição: Volume 7, Nº 10 (2021)
- Páginas: 89-93
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288693
- DOI: https://doi.org/10.18565/therapy.2021.10.89-93
- ID: 288693
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Osteoporosis is a chronic systemic disease of the skeleton, characterized by low bone mass and deterioration of its quality, which leads to increased fragility of bone tissue. In recent years, due to the understanding of the pathogenesis of the disease, significant therapeutic advances in the treatment of osteoporosis have been made. Despite the availability of many therapeutic medicaments to reduce the risk of fractures, osteoporosis remains a global problem in aging population in many countries, and the burden of osteoporotic fractures remains high, affecting the quality of life of suffering persons. This is connected first of all with comorbidity of osteoporosis and other diseases in senior age groups persons.
Palavras-chave
Texto integral
Sobre autores
Elena Zhugrova
I.I. Mechnikov North-Western state medical university of the Ministry of Healthcare of Russia
Email: jugrova@mail.ru
PhD, associate professor of the Department of therapy, rheumatology, examination of temporary disability and quality of medical care named after E.E. Eichwald
Vadim Mazurov
I.I. Mechnikov North-Western state medical university of the Ministry of Healthcare of Russia
Email: maz.nwgmu@yandex.ru
MD, professor, academician of RAS, head of the Department of therapy, rheumatology, examination of temporary disability and quality of medical care named after E.E. Eichwald
Bibliografia
- Wade S.W., Strader C., Fitzpatrick L.A. et al. Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos. 2014; 9: 182. doi: 10.1007/s11657-014-0182-3.
- World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level: Summary meeting report, Brussels, Belgium, 5-7 May 2004. Available at: http://www.who.int/chp/topics/Osteoporosis.pdf (date of access - 01.12.2021).
- European Prospective Osteoporosis Study (EPOS) Group, Felsenberg D., Silman A.J., Lunt M. et al. Incidence of vertebral fracture in Europe: Results from the European prospective osteoporosis study (EPOS). J. Bone Miner Res. 2002; 17(4): 716-24. doi: 10.1359/jbmr2002.17.4.716.
- Du Y., Zhao L.-J., Xu Q. et al. Socioeconomic status and bone mineral density in adults by race/ethnicity and gender: the Louisiana osteoporosis study. Osteoporos Int. 2017; 28(5): 1699-709. doi: 10.1007/s00198-017-3951-1.
- Puth M.T., Klaschik M., Schmid M. et al. Prevalence and comorbidity of osteoporosis- a cross-sectional analysis on 10,660 adults aged 50 years and older in Germany. BMC Musculoskelet Disord. 2018; 19(1): 144. doi: 10.1186/s12891-018-2060-4.
- Ховасова Н.О., Наумов А.В., Ткачева О.Н., Дудинская Е.Н. Характеристика гериатрического и соматического статуса у пациентов с остеопорозом. Проблемы эндокринологии. 2021; 3: 45-54. https://doi.org/10.14341/probl12751.
- Agborsangaya C.B., Lau D., Lahtinen M. et al. Multimorbidity prevalence and patterns across socioeconomic determinants: A crosssectional survey. BMC Public Health. 2012 Mar; 12: 201. doi: 10.1186/1471-2458-12-201.
- Клинические рекомендации. Остеопороз. Российская ассоциация эндокринологов, общественная организация «Российская ассоциация по остеопорозу», Ассоциация ревматологов России, Ассоциация травматологов-ортопедов России, Ассоциация гинекологов-эндокринологов России, Общероссийская общественная организация «Российская ассоциация геронтологов и гериатров». 2021. Рубрикатор клинических рекомендаций Минздрава России. Доступ: https://cr.minzdrav.gov.ru/schema/87_4 (дата обращения - 01.12.2021).
- Bischoff-Ferrari H.A., Willett W.C., Wong J.B. et al. Prevention of nonvertebral fractures with oral vitamin D. and dose dependency: A meta-analysis of randomized controlled trials. Arch Intern Med. 2009; 169(6): 551-61. doi: 10.1001/archinternmed.2008.600.
- Keen R. Osteoporosis: strategies for prevention and management. Best Pract Res Clin Rheumatol. 2007; 21(1): 109-22. doi: 10.1016/j. berh.2006.10.004.
- Boonen S., Sellmeyer D.E., Lippuner K. et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008; 74(5): 641-48. doi: 10.1038/ki.2008.193.
- Kendler D., Chines A., Clark P. et al. Bone mineral density after transitioning from denosumab to alendronate. J. Clin Endocrinol Metab. 2020; 105(3): e255-64. doi: 10.1210/clinem/dgz095.
- Reid I.R. Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol. 2015; 11(7): 418-28. doi: 10.1038/ nrendo.2015.71.
- Miller P.D., Pannacciulli N., Brown J.P. et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J. Clin Endocrinol Metab. 2016; 101(8): 3163 -70. doi: 10.1210/jc.2016-1801.
- Bone H.G., Wagman R.B., Brandi M.L. et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5(7): 513-23. doi: 10.1016/ S2213-8587(17)30138-9.
- Miller P.D., Pannacciulli N., Malouf-Sierra J. et al. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. 2020; 31(1): 181-91. doi: 10.1007/s00198-019-05233-x.
- Jiang Y., Zhao J.J., Mitlak B.H. et al. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner Res. 2003; 18(11): 1932-41. doi: 10.1359/jbmr.2003.18.11.1932.
- Rajzbaum G., Jakob F., Karras D. et al. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin. 2008; 24(2): 377-84. doi: 10.1185/030079908x261087.
- Gafni R.I., Langman C.B., Guthrie L.C. et al. Hypocitraturia is an untoward side effect of synthetic human parathyroid hormone (hPTH] 1-34 therapy in hypoparathyroidism that may increase renal morbidity. J. Bone Miner Res. 2018; 33(10): 1741-47. doi: 10.1002/jbmr.3480.
- Пашенцева А.В., Вербовой А.Ф., Косарева О.В., Шаронова Л.А. Современные возможности терапии остеопороза. Фарматека. 2016; 5: 22-29.
- Kawate H., Takayanagi R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. Clin Interv Aging. 2011; 6: 151-60. doi: 10.2147/CIA.S15711.
- European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007. Available at: https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-changes-product-information-protelos-osseor-due-risk-severe (date of access - 01.12.2021).
Arquivos suplementares
